Look back at pharma news in the week to May 29, 2020

31 May 2020

By Barbara Obstoj-Cardwell. Editor

USA-based Sunovion had good news last week, as the US Food and Drug Administration finally approved its apomorphine, now trade named Kynmobi, sublingual film for the treatment of Parkinson’s disease OFF episodes. French pharma major Sanofi announced it plans to sell its around 20% equity stake in US development partner Regeneron Pharmaceuticals. On the deal-making front, Gilead Sciences entered into an immune-oncology collaboration with Arcus Biosciences worth a total of up to $2 billion. And late-comer to the COVID-19 treatment arena, Merck & Co, announced not one, but three deals, including the acquisition of Themis, and partnerships with IAVI and Ridgeback.

Sunovion’s novel sublingual formulation will address major unmet need in Parkinson’s treatment

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK